Medical Oncologist
Targeted treatment
CDK4/6 inhibitors in early breast cancer after surgery
For some women with higher-risk early hormone-sensitive, HER2-negative breast cancer, adding abemaciclib for two years or ribociclib for three years to hormone therapy after surgery lowers recurrence further. This page explains, in general terms, who is considered and what treatment involves.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Why are CDK4/6 inhibitors given after surgery for early breast cancer?
- Abemaciclib and ribociclib after surgery, in general terms
- What your oncologist weighs
- The vocabulary, in plain language
- Weighing the benefit honestly
- What the first months usually involve
- Fitting treatment around work and family
- What makes an early breast cancer higher risk
- What happens when the CDK4/6 inhibitor course ends
- What people assume about CDK4/6 inhibitors after surgery
- Common questions about CDK4/6 inhibitors after surgery
The short answer
Why are CDK4/6 inhibitors given after surgery for early breast cancer?
For some women with early hormone receptor positive, HER2-negative breast cancer that has a higher chance of returning, adding a CDK4/6 inhibitor to hormone therapy after surgery lowers that chance further. Abemaciclib, taken for two years, has been shown to reduce recurrence in women with node-positive, high-risk cancers. Ribociclib, taken for three years, has shown benefit in a broader group including some node-negative higher-risk cancers. Hormone therapy continues for several years alongside and after the CDK4/6 inhibitor.
Who is usually considered
Women whose cancer spread to several lymph nodes, or involved fewer nodes with other high-risk features such as a large tumour or high grade. The exact criteria depend on the drug and the study evidence.
What treatment involves
Daily tablets for a fixed period of two or three years, with regular blood tests, liver checks and, for ribociclib, heart tracings. Hormone therapy is taken at the same time and continues afterwards.
Who may not benefit enough
Women with lower-risk early cancers, for whom the added benefit is small compared with the side effects, cost and frequent monitoring.
This page gives general information only. Whether this treatment suits you is a decision for your oncologist.Side by side
Abemaciclib and ribociclib after surgery, in general terms
Abemaciclib
Ribociclib
Taken for two years
Taken for three years
Node-positive, high-risk cancers
A broader group, including some node-negative
Twice daily, continuously
Once daily, three weeks on, one off
Loose motions most common
Low white counts, liver and heart checks
Given with hormone therapy
Given with hormone therapy
Deciding
What your oncologist weighs
The benefit is meaningful for higher-risk women, but the treatment is demanding.
Your cancer's risk
Number of lymph nodes, tumour size, grade and sometimes Ki-67 help estimate how much benefit is likely.
Your health
Heart rhythm, liver function, bowel health and other medicines affect which drug is suitable.
An ECG may be needed first.Side effects and daily life
Frequent tests and side effects over two or three years matter for work, travel and quality of life.
Cost and access
These drugs are costly. Support programmes and insurance coverage should be explored early.
Questions to ask
- How much would this lower my risk?
- Which drug suits me and why?
- What support is available for cost?
Words you will hear
The vocabulary, in plain language
- Adjuvant therapy
- Treatment after surgery to lower the chance of recurrence.
- Node-positive
- Cancer found in the lymph nodes removed at surgery.
- Invasive disease-free survival
- The time without invasive cancer returning, used to measure benefit in studies.
- Ki-67
- A marker of how quickly cancer cells are dividing.
- CDK4/6 inhibitor
- A tablet that blocks proteins cancer cells need to divide.
- Dose reduction
- Lowering the dose to manage side effects, common and acceptable.
Being straight with you
Weighing the benefit honestly
For higher-risk early breast cancer, adding a CDK4/6 inhibitor lowers the chance of the cancer returning in a meaningful way. It does not remove that chance, and the benefit on overall survival is still being clarified for some groups as studies continue.
It is a big commitment
Two or three years of daily tablets, regular blood tests and managing side effects is demanding, especially after surgery, chemotherapy and radiation. Many women find the first months hardest.
Dose adjustments help people continue
Many women need dose changes, particularly for loose motions or low counts. This is expected and helps people complete treatment.
Stopping early is sometimes necessary
If side effects are severe despite adjustments, stopping the CDK4/6 inhibitor while continuing hormone therapy is a reasonable choice to discuss.
What this page cannot tell you
It cannot tell you how much benefit you would gain. Ask your oncologist for an estimate based on your cancer.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Getting started
What the first months usually involve
The beginning of treatment is when side effects and tests are most frequent. Preparing for it helps you settle in.
With abemaciclib
Loose motions often start in the first week or two. Having anti-diarrhoea medicine at home before starting, drinking plenty of fluids and reporting early help keep it under control. It usually becomes less troublesome after the first couple of months.
With ribociclib
Blood tests every two weeks and heart tracings in the first cycles check white counts, liver function and heart rhythm. Some women need a pause or lower dose early on.
For both
Tiredness is common. Gentle exercise, good sleep and pacing daily tasks help. Report fever, persistent loose motions, yellowing of the skin or breathlessness promptly.
Work and family
Fitting treatment around work and family
Many women return to work or family responsibilities while taking these tablets. Planning makes it easier.
Schedule tests
Ask whether blood tests can be done near home or work, and book them early in the day.
Plan for side effects
Knowing where toilets are, carrying medicines and allowing rest days helps in the early months.
Talk to your employer
Flexible hours or working from home on some days can make a long course of treatment more manageable.
Understanding your risk
What makes an early breast cancer higher risk
The decision to add a CDK4/6 inhibitor depends on how likely the cancer is to return despite surgery and hormone therapy. Your pathology report holds most of the answers.
Lymph node involvement
Cancer found in several lymph nodes under the arm is one of the strongest signs of higher risk. The more nodes involved, the greater the chance of recurrence and the more a CDK4/6 inhibitor may add.
Tumour size and grade
Larger tumours and high-grade cancers, whose cells look more abnormal and divide faster, carry more risk even when fewer nodes are involved.
Growth markers
A high Ki-67 score or a high-risk genomic test result may add to the picture, though criteria differ between the drugs.
Response to treatment before surgery
If chemotherapy or hormone therapy was given before surgery and cancer remained in the breast or nodes, this can also indicate higher risk.
Putting it together
Your oncologist combines these features to estimate your risk and the likely benefit, then explains it in plain terms so you can decide together.
After the course
What happens when the CDK4/6 inhibitor course ends
Finishing two or three years of tablets is a milestone, but hormone therapy and follow-up continue.
Hormone therapy continues
Tamoxifen or an aromatase inhibitor usually carries on for a total of at least five years, sometimes longer.
Follow-up continues
Regular clinic reviews, yearly mammograms and attention to bone and heart health carry on as before. Report any new lump, bone pain that does not settle or other new symptoms promptly rather than waiting for your next appointment.
Side effects settle
Loose motions, low counts and tiredness from the CDK4/6 inhibitor usually ease within weeks of stopping.
Commonly believed
What people assume about CDK4/6 inhibitors after surgery
Everyone with hormone-sensitive breast cancer needs one.
They are for selected higher-risk women. Many women with lower-risk cancers do very well with hormone therapy alone.
If I need a lower dose, it will not work.
Dose reductions are common and appear to keep the benefit.
The CDK4/6 inhibitor replaces hormone therapy.
It is taken with hormone therapy, which continues for years afterwards.
Loose motions mean I must stop.
They are usually controlled with medicine and dose changes. Report them early.
Questions we are asked
Common questions about CDK4/6 inhibitors after surgery
Will I definitely be offered one?
Only if your cancer meets higher-risk criteria and the benefit outweighs the burden. Ask your oncologist whether you qualify and why.
Can I start after finishing radiation?
Usually yes. Timing is planned around surgery, chemotherapy and radiation.
Does it affect fertility?
Pregnancy is not safe during treatment. Discuss fertility and contraception before starting.
How often are blood tests needed?
Often every two weeks at first, then monthly, then less often once stable.
Can I drink alcohol?
Limit alcohol, as it can affect the liver and worsen side effects. Ask your team.
What if I cannot afford it?
Tell your team early. Support programmes, insurance or schemes may help, and hormone therapy alone remains effective.
Can I switch between the two drugs?
Occasionally, for side effects. Discuss it with your oncologist.
Where can I read about my own drug?
Your oncology team will give you written information about your treatment. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Journal of Clinical Oncology — Abemaciclib combined with endocrine therapy for high-risk early breast cancer (monarchE)
- New England Journal of Medicine — Ribociclib plus endocrine therapy in early breast cancer (NATALEE)
- National Cancer Institute — Breast cancer treatment (PDQ)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.